Interestingly, clobazam, which has preferential affinity for the GABRA2 subunit, offers some therapeutic benefit in Dravet syndrome patients [17–19,42,43]. Here, GABRA2 is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.